Prostatype Genomics AB ("Prostatype Genomics" or "the Company") today announces that the recently executed warrant exercise of warrants of series TO 2 has been registered at the Companies Registration Office.
In total 2,622 warrants of series TO 2 were exercised during the exercise period 9-30 March 2023. The Swedish Companies Registration Office has now registered the warrant exercise and the total number of shares after the registration amounts to 22,862,119 shares and the share capital amounts to SEK 1,371,727.14.
The conversion from interim shares to ordinary shares is expected to take place around 18 April 2023 and ordinary shares are expected to be visible in the subscriber's account approximately two banking days after.
For further information about TO 2, please contact
Sedermera Corporate Finance AB
Phone: +46 (0) 40 615 14 10
E-mail: cf@sedermera.se
Webpage: www.sedermera.se
Nordic Issuing AB
Phone: +46 (0) 40 632 00 20
E-mail: info@nordic-issuing.se
Webpage: www.nordic-issuing.se
For further information about Prostatype Genomics, please contact
Nicklas Rosendal
E-mail: nicklas.rosendal@prostatypegenomics.com
Certified Advisor
Svensk Kapitalmarknadsgranskning AB
Phone: +46 (0) 11-32 30 732
E-mail: ca@skmg.se
Prostatype® is a genetic test that is available to patients and treating urologists as a supplementary decision basis for the question of treatment or not treatment of prostate cancer. The test is developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.